Shortly before Regeneron Pharmaceuticals won the right last year to sell a new drug for severe eczema, the company’s chief executive promised to price the medicine “responsibly” in order to avoid the anger over high drug prices. At first blush, he appeared to have succeeded – the $37,000 price tag for Dupixent was in line with an evaluation by a closely followed cost-effectiveness watchdog.

But a year later, the effort has not produced all of the desired results. Regeneron has, indeed, escaped public criticism for its pricing, which is something of a moral victory for Dr. Len Schleifer, the outspoken chief executive. However, a majority of physicians report that access to the medicine is still being “tightly controlled and restricted” by payers, according to a newly released survey of dermatologists by Leerink analysts.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy